Therapeutic Area | MeSH |
---|---|
infections | D007239 |
eye diseases | D005128 |
immune system diseases | D007154 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
VALCYTE | CHEPLAPHARM Arzneimittel | N-021304 RX | 2001-03-29 | 1 products, RLD, RS |
VALCYTE | CHEPLAPHARM Arzneimittel | N-022257 RX | 2009-08-28 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
valcyte | New Drug Application | 2025-01-10 |
valganciclovir | ANDA | 2025-03-10 |
valganciclovir hydrochloride | ANDA | 2024-05-27 |
valganciclovir hydrochloride for oral | ANDA | 2023-10-17 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
cytomegalovirus infections | EFO_0001062 | D003586 | B25 |
aids-related opportunistic infections | — | D017088 | — |
cytomegalovirus retinitis | EFO_1001302 | D017726 | — |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 2 | — | — | — | — | 2 |
Malnutrition | D044342 | EFO_0008572 | E40-E46 | 1 | — | — | — | — | 1 |
Drug common name | Valganciclovir |
INN | valganciclovir |
Description | Valganciclovir is the L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine. It has a role as a prodrug and an antiviral drug. It is a member of purines and a L-valyl ester. It is functionally related to a guanine and a ganciclovir. |
Classification | Small molecule |
Drug class | antivirals: antivirals (acyclovir type) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC(C)[C@H](N)C(=O)OCC(CO)OCn1cnc2c(=O)[nH]c(N)nc21 |
PDB | — |
CAS-ID | 175865-60-8 |
RxCUI | — |
ChEMBL ID | CHEMBL1201314 |
ChEBI ID | 63635 |
PubChem CID | 135413535 |
DrugBank | DB01610 |
UNII ID | GCU97FKN3R (ChemIDplus, GSRS) |